Personalized ctDNA for Monitoring Disease Status in Head and Neck Squamous Cell Carcinoma.

ABSTRACT:

Purpose

Many patients with locoregionally advanced human papillomavirus-negative head and neck squamous cell carcinoma (HNSCC) relapse. ctDNA has the potential to identify minimal residual disease, but its clinical utility for virus-negative HNSCC is not well understood.

Experimental design

We retrospectively evaluated a personalized, commercial ctDNA assay (Signatera, Natera) during clinical care of patients treated for predominantly newly diagnosed human papillomavirus-negative HNSCC. Signatera utilizes 16-plex PCR from matched tumor and blood. Objectives were to understand ctDNA detectability and correlate changes posttreatment with disease outcomes.

Results

Testing was successful in 100/116 (86%) patients (median age: 65 years, 68% male, 65% smokers); testing fail

SUBMITTER: Hanna GJ 

PROVIDER: S-EPMC11292193 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature